Drug Profile


Alternative Names: E-7438; EPZ-6438

Latest Information Update: 29 Apr 2017

Price : $50

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma

Most Recent Events

  • 25 Apr 2017 Tazemetostat receives Fast Track designation for Follicular lymphoma [PO] (Second-line therapy or greater, Monotherapy) in USA
  • 09 Mar 2017 Epizyme plans a combination study of Tazemetostat and Prednisolone in Follicular lymphoma in 2017
  • 18 Jan 2017 Epizyme plans a phase I trial for Diffuse large cell lymphoma and Mantle Cell Lymphoma (Second-line therapy or greater) in USA (PO) (NCT03028103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top